Loading
CS
Conexeu Sciences Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Purcell Lynn Sebastian, was filed 23 Jun 2026.
Conexeu Sciences Inc.: what insiders have been doing
This page follows insider dealings at Conexeu Sciences Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 19 October 2025 to 19 October 2026, the disclosure feed for Conexeu Sciences Inc. logged 9 filings by 5 insiders.
Only purchases show up on the open market, 2 purchases in all worth €288k, filed by 1 insider. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 senior executive among the declarants. Biggest ticket of the year: €288k, bought by Purcell Lynn Sebastian and made public on 14 May 2026.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 23 June 2026, which is 118 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (5,814 companies, median 19 filings), a count of 9 filings is below the norm. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
10
Thresholds
n/a
Buy Volume
€288,017
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleLynn Sebastian Purcell2 buys
OnePointTwo Capital Ventures LLC1 buy
Since the insiders bought
- -39.0%Entry US$13.07 · Close at T+90 US$7.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended October 2025 · cache
US$3.65
Analyst consensus
1 analystsUS$20.00Target US$20.00(+449%)US$20.00
Income statement
EBITDA-US$3.9M
Net income-US$3.9M0.0% margin
Valuation
P/Book17.0x
Balance sheet & cash
Market capUS$102.8M
Total debtUS$98.1k
Free Cash Flow-US$1.7M
Debt / Equity8%
Profitability & ownership
ROE-332.9%
ROA-170.7%
% insiders52.1%
% institutions7.6%
Last declaration on 28 September 2026
Declarations10 total
750,000 shares@ US$0.001100.0% of flowCommon StockSEC:0001062993-26-005090:0
500,000 shares@ US$0.00150.1% of flowCommon StockSEC:0001062993-26-004966:0
217,608 shares@ US$2.30100.0% of flowCommon StockSEC:0002128469-26-000007:0
202,500 sharesCommon StockSEC:0002128469-26-000005:0
Canonical exit: 16 Sept 2026 (T+90)
250,000 sharesCommon StockSEC:0002137182-26-000003:0
400,000 shares@ US$0.001100.0% of flowCommon StockSEC:0002137182-26-000002:0
500,000 shares@ US$0.00149.9% of flowCommon StockSEC:0001062993-26-002870:0
11,175 shares0Common StockSEC:0001062993-26-002732:0
422,500 shares@ US$0.80100.0% of flowCommon StockSEC:0002128469-26-000004:0
Canonical exit: 10 Aug 2026 (T+90)
▲
Same trade as the filing by Lynn Sebastian Purcell, counted once · View ↗
422,500 shares@ US$0.80100.0% of flowCommon StockSEC:0002080820-26-000002:0
Canonical exit: 10 Aug 2026 (T+90)
10 of 10 declarations
About Conexeu Sciences Inc.
Conexeu Sciences Inc. is a United States-based biotechnology and medical technology company headquartered in Reno, Nevada, and positioned to trade on the NASDAQ market. Founded in 2022, the company is developing CXU™, an investigational, preclinical medical device candidate built around a patented collagen-based extracellular matrix (ECM) scaffold. Conexeu’s core proposition is to provide a temporary structural framework intended to support tissue regeneration, rather than simply replace tissue with a short-term cosmetic or mechanical solution. ([conexeu.com](https://conexeu.com/tissue-repair/?utm_source=openai))
The company’s business model is best understood as a platform strategy. Instead of focusing on a single narrow indication, Conexeu presents CXU as a foundational biomaterial that may be extended across multiple high-value markets, including wound care, medical aesthetics, oral tissue restoration, veterinary health, and, in the longer term, 3D bioprinting and tissue reconstruction. This breadth matters competitively because the regenerative medicine market is crowded with partial solutions, while demand continues to grow for biologically inspired alternatives to synthetic fillers, grafts, and traditional implants. ([conexeu.com](https://www.conexeu.com/platform/cxu?utm_source=openai))
Read moreShow less
Recent corporate activity suggests a company in early commercialization preparation rather than full product launch. In October 2025, Conexeu announced the completion of a maximum $5 million Reg CF financing round, a meaningful milestone for a preclinical issuer and an indication of investor interest in its patented collagen platform. In 2026, the company highlighted a broader “Architecting Bioregeneration” thesis and disclosed progress around 3D-printed structures made from its functional ECM. Public filings and market coverage also indicated that Conexeu expected a NASDAQ direct listing, reinforcing its ambition to access public capital markets in the United States. ([conexeu.com](https://conexeu.com/conexeu-sciences-closes-maximum-5m-reg-cf-financing/?utm_source=openai))
From an equity analyst perspective, Conexeu should be viewed as a high-risk, high-upside preclinical biotech story. The competitive edge rests on differentiated collagen science, a patented technology base, and management’s effort to build a multi-application platform with potential clinical and commercial relevance. At the same time, the investment case remains dependent on regulatory progress, preclinical validation, and the company’s ability to translate scientific promise into scalable, reimbursable, and marketable products. For French-speaking investors, the name is therefore best framed as an early-stage regenerative medicine platform with optionality across several adjacent healthcare verticals, but with substantial execution and dilution risk typical of development-stage life sciences issuers. ([conexeu.com](https://www.conexeu.com/the-platform-strategy-cxu?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
